ITF Therapeutics
ITF Therapeutics is seeking a Thought Leader Liaison to cover the East Territory, responsible for developing strategic relationships with key opinion leaders and healthcare professionals in the Neuromuscular/Duchenne Muscular Dystrophy space. This field-based marketing role serves as the primary commercial contact for high-priority thought leaders and acts as the field-based extension of Marketing. The position involves driving strategic engagement, generating marketplace insights, and supporting speaker development while ensuring compliance with all legal and regulatory requirements.
Headquarters
Concord, Massachusetts, United States
Company Size
1-10 employees
Founded
2024
ITF Therapeutics LLC is the United States affiliate of Italfarmaco S.p.A., founded in 2024 and based in Concord, MA. The company focuses on bringing therapeutic options to people living with rare diseases, most notably commercializing DUVYZAT (givinostat), an FDA‑approved HDAC inhibitor for Duchenne muscular dystrophy (DMD), in the U.S. market. ITF combines a flexible, entrepreneurial approach with the resources and legacy of its parent organization to deliver treatments, support programs, and educational resources for patients, clinicians, and researchers.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ITF Therapeutics.
19% above the average for this role